PMV Pharmaceuticals Inc Ordinary Shares PMVP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
-
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
-
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
-
PMV Pharma Announces Proposed Public Offering of Securities
-
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
-
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
Trading Information
- Previous Close Price
- $1.31
- Day Range
- $1.26–1.33
- 52-Week Range
- $1.02–1.91
- Bid/Ask
- $1.25 / $1.70
- Shares Outstanding
- 75.51M
- Market Cap
- $67.89M
- Volume/Avg
- 171,002 / 653,172
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 54
- Website
- https://www.pmvpharma.com
Valuation
|
Metric
|
PMVP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.95 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PMVP
Financial Strength
|
Metric
|
PMVP
|
|---|---|
Quick Ratio | 7.52 |
Current Ratio | 7.70 |
Interest Coverage | — |
Quick Ratio
PMVP
Profitability
|
Metric
|
PMVP
|
|---|---|
Return on Assets (Normalized) | −60.76% |
Return on Equity (Normalized) | −67.24% |
Return on Invested Capital (Normalized) | −70.17% |
Return on Assets
PMVP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|M#C@zc | LOCK|r^<<j | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|T&$L?! | LOCK|@j^^ | $83B | |||
| Moderna Inc
MRNA
| LOCK|fg&^?$ | LOCK|pB% | $80B | |||
| argenx SE ADR
ARGX
| LOCK|xs$cY< | LOCK|$c& | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|T@!$?> | LOCK|PJ# | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>Z!G>y | LOCK|QDTD! | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Z<Dh?Hh | LOCK|%Dcm& | $28B | |||
| Incyte Corp
INCY
| LOCK|qqK>ggk | LOCK|Sp | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Py^$>^ | LOCK|rS$ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#D#sT!^ | LOCK|lW# | $14B |
United States